I'm always excited for new data on new treatments and old treatments. Anytime we get really excited about a new potential molecule that we see phase 1 and phase 2 data for, we need that big phase 3 ...

As benchmarking is now becoming a part of payment models, practices realize they need comparative data to understand how well they perform relative to their competitors and whether there is room for ...

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial ...

Comparing the risks and benefits of new drugs against those already on the market will help ensure that patients receive the best treatment, but a lack of data is hindering GPs and clinicians, finds ...

In recent years, there has been growing discussion about digital public infrastructure (DPI)—systems such as digital identity systems, alternative payment methods, and data exchanges that are backed ...